
Hancock Jaffe Laboratories, Inc. HJLI
Hancock Jaffe Laboratories, Inc. Deferred Revenue 2011-2026 | HJLI
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Hancock Jaffe Laboratories, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 33 | 33 K | 33 K | 103 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 103 K | 33 | 42.4 K |
Deferred Revenue of other stocks in the Medical devices industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
508 K | - | - | $ 1.77 B | ||
|
Allied Healthcare Products
AHPI
|
563 K | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
424 K | - | -5.86 % | $ 30.6 M | ||
|
Apollo Endosurgery
APEN
|
88 K | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
10.4 M | - | - | $ 1.05 B | ||
|
EDAP TMS S.A.
EDAP
|
3.41 M | $ 3.6 | 4.2 % | $ 135 M | ||
|
Aziyo Biologics
AZYO
|
533 K | - | 1.37 % | $ 20.5 M | ||
|
BioSig Technologies
BSGM
|
16 K | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
2.45 M | - | -13.19 % | $ 166 K | ||
|
Helius Medical Technologies
HSDT
|
148 K | $ 2.22 | 2.78 % | $ 1.35 M | ||
|
Conformis
CFMS
|
215 K | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
1.67 M | $ 11.47 | 3.33 % | $ 325 M | ||
|
Cardiovascular Systems
CSII
|
2.11 M | - | 0.15 % | $ 844 M | ||
|
CryoLife, Inc.
CRY
|
1.45 M | - | -4.14 % | $ 702 M | ||
|
Cytosorbents Corporation
CTSO
|
182 K | $ 0.57 | -5.8 % | $ 35.5 M | ||
|
LivaNova PLC
LIVN
|
11.5 M | $ 66.26 | 15.05 % | $ 3.61 B | ||
|
Delcath Systems
DCTH
|
170 K | $ 11.26 | -2.34 % | $ 403 M | ||
|
Itamar Medical Ltd.
ITMR
|
732 K | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
13.3 K | - | - | $ 462 M | ||
|
IRIDEX Corporation
IRIX
|
2.16 M | $ 1.04 | -0.95 % | $ 17.6 M | ||
|
Dynatronics Corporation
DYNT
|
150 K | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
621 K | - | - | $ 10.2 M | ||
|
Myomo
MYO
|
2.51 K | $ 0.85 | -2.78 % | $ 35.6 M | ||
|
Butterfly Network
BFLY
|
16.1 M | $ 4.55 | -5.6 % | $ 963 M | ||
|
Intersect ENT, Inc.
XENT
|
137 K | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
335 K | - | -0.97 % | $ 54.4 M | ||
|
Insulet Corporation
PODD
|
14 M | - | - | $ 10.6 B | ||
|
Globus Medical
GMED
|
27.7 M | $ 89.22 | -0.9 % | $ 12.1 B | ||
|
Sintx Technologies
SINT
|
4.72 K | $ 2.4 | -0.83 % | $ 6.66 M | ||
|
Integer Holdings Corporation
ITGR
|
5.21 M | $ 86.29 | 0.51 % | $ 3 B | ||
|
Invacare Corporation
IVC
|
2.28 M | - | - | $ 24.7 M | ||
|
TransMedics Group
TMDX
|
2.9 M | - | - | $ 2.48 B | ||
|
Tandem Diabetes Care
TNDM
|
9.53 M | - | - | $ 1.23 B | ||
|
LENSAR
LNSR
|
2.6 M | $ 5.39 | -1.73 % | $ 64.5 M |